2-Plants: Anti-caries drug grown in tobacco - the most advanced GEpharma crop

[GENET <coordination@genet-info.org>]

-------------------------------- GENET-news -------------------------------

TITLE:  LARGE SCALE BIOLOGY CORPORATION AND PLANET BIOTECHNOLOGY INC
        ANNOUNCE BIOMANUFACTURING AGREEMENT
SOURCE: Large Scale Biology Corporation and Planet Biotechnology Inc., USA
        Press Release
        http://www.lsbc.com/index.php
DATE:   15 Jul 2004

------------------- archive: http://www.genet-info.org/ -------------------


LARGE SCALE BIOLOGY CORPORATION AND PLANET BIOTECHNOLOGY INC ANNOUNCE
BIOMANUFACTURING AGREEMENT

VACAVILLE, CALIFORNIA, July 15, 2004 - Large Scale Biology Corporation
and privately held Planet Biotechnology Inc. (Planet) of Hayward,
California, today announced initiation of a biomanufacturing agreement to
extract and purify Planet's lead product, CaroRx(TM), a plant-made
antibody to control dental caries. Planet's CaroRx(TM) is the world's
first recombinant plant-made antibody to be clinically tested, and has
been shown to prevent the adhesion of tooth decay causing bacteria to the
tooth surface. Planet's tobacco plants expressing CaroRx(TM) secretory
IgA will be extracted by LSBC at its Owensboro, Kentucky, manufacturing
facility. CaroRx(TM) has completed Phase I clinical trials under an
approved U.S. FDA Investigational New Drug (IND) application. "The
experience and manufacturing capabilities that LSBC offers in the area of
plant-produced recombinant protein extraction complements our proprietary
gene expression and product development technologies," stated Elliott
Fineman, President and CEO of Planet Biotechnology. "Larger quantities of
CaroRx(TM) are needed for our expanded clinical trials, and testing of
formulations for the European market. We are happy to be working with
LSBC during the scale-up phase of product development," Mr. Fineman
added. "We are pleased to be working with Planet, a true pioneer in the
development of plant-produced antibodies, as they expand their
development program for their exciting new product, CaroRx(TM)," said
Kevin Ryan, LSBC's President and CEO. Our new agreement with Planet
further exemplifies LSBC's leadership role in the manufacture of plant-
made pharmaceuticals and demonstrates the versatility of our Owensboro
manufacturing facility in the extraction of a wide range of products,"
Mr. Ryan added.


Contact:
Large Scale Biology Corporation
(707) 446 5501
Ronald J. Artale
Chief Operating Officer (707) 446 5501, x320


For additional information on LSBC's technologies and products, please
contact:
Daniel Tusé, Ph.D.
Vice President Business Development
Tel 707 469 2316
Fax 707 446 3917
Email: daniel.tuse@lsbc.com


About Large Scale Biology Corporation Large Scale Biology uses its
proprietary gene expression, molecular engineering and bioprocessing
technologies to develop and manufacture therapeutic and industrial
proteins, vaccines and diagnostic products for effective characterization
and treatment of disease. Corporate offices, R&D laboratories and Eclipse
Diagnostics Inc. are headquartered in Vacaville, California, and the
Company's commercial-scale biomanufacturing facility is located in
Owensboro, Kentucky. For more information about Large Scale Biology
Corporation, visit the Company's website at www.lsbc.com.

About Planet Biotechnology, Inc. Planet Biotechnology, Inc. is a
privately held, clinical-stage company whose mission is to discover,
develop and commercialize new monoclonal-antibody-based therapeutic and
preventative products to meet significantly underserved medical needs.
The Company's unique plant-derived antibody-based products
("plantibodies") have been produced through cultivation of genetically
modified tobacco. Planet's headquarters and product development
laboratories are located in Hayward, California. For additional
information on Planet Biotechnology Inc. please visit the Company's
website at www.planetbiotechnology.com.

This release contains forward-looking statements about applications of
LSBC's technologies and potential markets for product of one of our
collaborators. These forward-looking statements involve risks,
uncertainties and situations that may cause our actual results to differ
materially from those implied by these statements, including our ability
to commercialize one of our products, the ability of our collaborators to
sell products we extract or make for them, the effectiveness of our and
our collaborators' technologies to produce specific products and/or in a
cost-effective manner, any difficulties or delays in obtaining regulatory
approval to test and market such products, and the requirement of
substantial funding for us to preserve our technology base and product
pipeline. We cannot guarantee future results. You should not place undue
reliance on these forward-looking statements, which apply only as of the
date of this release. For a further list and description of such risks
and uncertainties see the reports filed by Large Scale Biology
Corporation with the Securities and Exchange Commission, including our
reports on Forms 10-K and 10-Q. Except as required by law, we do not
undertake to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.

LSBC(TM), our logo and GENEWARE® are trademarks of Large Scale Biology

Corporation. Planet and CaroRx(TM)are trademarks of Planet Biotechnology, Inc.




--


GENET
European NGO Network on Genetic Engineering

Hartmut MEYER (Mr)
Kleine Wiese 6
D - 38116 Braunschweig
Germany

P: +49-531-5168746
F: +49-531-5168747
M: +49-162-1054755
E: coordination(*)genet-info.org
W: <http://www.genet-info.org>



-----------------------------
   GENET-news mailing list
-----------------------------